When new data emerges that impacts a drug it can demand a rapid adjustment of marketing, sales and communications activity. And in certain instances, as our client discovered, it can mean a complete rebrand and relaunch. That’s no easy task when you’re also running a business and managing commercial alliances. Thankfully, our proven track record in this area can provide the necessary capability and expertise.
Clinical data for a new, large indication meant our client had to rethink their primary care drug’s commercial strategy. However, as a major multinational, this was a complex effort. They had to develop a strategy and execute this while also running the business, without increasing staff headcount, and within the context of a commercial partnership with another pharma. We were selected to support their relaunch and rebrand because of our expertise in blockbuster launches and our ability to deploy a targeted team with a bespoke combination of skills.
Our team worked closely with the Therapeutic Area and brand leadership to:
We supported the execution of a world-class launch meeting and the subsequent launch. The performance and execution exceeded projections. We delivered pre-launch training for 2,500+ sales professionals across both companies; including four programming tracks to address different specialties and customer types.
Suggested Case Studies
Tailoring business models that address the reality of an…
Agribusiness Strategy Implementation
Business models must be built in full alignment with an organization’s strategy and marketplace. But what do…